{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:59:09Z","timestamp":1761299949044,"version":"build-2065373602"},"reference-count":0,"publisher":"Salvia Medical Sciences Ltd","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Galen Med J"],"abstract":"<jats:p>Background: This meta-analysis aimed to evaluate the efficacy of Daratumumab compared to control treatments in multiple myeloma across subgroups, including relapsed or refractory (RRMM), newly diagnosed transplant-eligible (ND\/ESCT), and transplant-ineligible (ND\/ISCT) patients. Materials and Methods: A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science. Randomized controlled trials and comparative studies evaluating Daratumumab versus control treatments in multiple myeloma patients were included. A random-effects model was employed to calculate pooled effect estimates of overall response rate (ORR), progression or death (PRD), minimum residual disease (MRD) negativity, and mortality. Results: The analysis included data from 35 studies, 21 studies (n=7,604 patients) in the RRMM subgroup, 12 studies (n=10,216 patients) in the ND\/ISCT subgroup, and 6 studies (n=4,619 patients) in the ND\/ESCT subgroup, comprising 22,439 patients (including healthy controls). Daratumumab significantly improved ORR (OR: 2.58, 95% CI: 2.26\u20132.93, P&lt;0.01) and MRD negativity rates across all subgroups. PRD risk was lower in the Daratumumab group (RD: -0.14, 95% CI: -0.16 to -0.12), with consistent efficacy across RRMM, ND\/ESCT, and ND\/ISCT patients. Conclusion: This meta-analysis confirms Daratumumab's significant efficacy across multiple patient subgroups, providing broad clinical benefits in multiple myeloma treatment. While some heterogeneity and potential publication bias were observed, Daratumumab remains a robust therapeutic option for extending progression-free and overall survival.<\/jats:p>","DOI":"10.31661\/gmj.v14i.3958","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:56:49Z","timestamp":1761299809000},"page":"e3958","source":"Crossref","is-referenced-by-count":0,"title":["Daratumumab Versus Control Treatment:  A Systematic Review and Meta-analysis Study of Survival Outcomes Among Multiple Myeloma Patients"],"prefix":"10.31661","volume":"14","author":[{"given":"Pouria","family":"Salajegheh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirali","family":"Salajegheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Yazdi Yahyaabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzaneh","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16705","published-online":{"date-parts":[[2025,10,21]]},"container-title":["Galen Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/download\/3958\/3341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/download\/3958\/3342","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/download\/3958\/3341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:56:50Z","timestamp":1761299810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.salviapub.com\/index.php\/gmj\/article\/view\/3958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.31661\/gmj.v14i.3958","relation":{},"ISSN":["2322-2379","2588-2767"],"issn-type":[{"value":"2322-2379","type":"electronic"},{"value":"2588-2767","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}